marketing wars over the new sleeping pills
You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.
Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one approved for long-term use...but it has a bitter aftertaste in up to 30% of patients.
Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: PA includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote